N4 Pharma (N4P)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.65p
   
  • Change Today:
      0.000p
  • 52 Week High: 3.07
  • 52 Week Low: 0.50
  • Currency: UK Pounds
  • Shares Issued: 394.78m
  • Volume: 168,735
  • Market Cap: £2.57m

Growth Ratings

EPS Growth shows the relative growth of a company's earnings over the last year.

The rise in total monies receivable for goods / services sold before expenses.

1yr EPS Growth Not Available
1yr Revenue Growth Not Available

Income Ratings

The percentage of the share price that a company pays out as dividends over a year.

The percentage change from the previous year in the dividend paid on each share.

Dividend Yield Not Available
1yr DPS Growth Not Available

Valuation Ratings

The share price as a ratio of revenue per share.

The share price as a ratio of net asset value.

Price Sales Ratio
99.01% above the market average99.01% above the market average99.01% above the market average99.01% above the market average99.01% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Book Ratio
50.19% below the market average50.19% below the market average50.19% below the market average50.19% below the market average50.19% below the market average
2.33% below the sector average2.33% below the sector average2.33% below the sector average2.33% below the sector average2.33% below the sector average

Performance Ratings

In percentage total change in share price over 30 days.

In percentage total change in share price over 3 months.

Price Chg 30d
75.91% above the market average75.91% above the market average75.91% above the market average75.91% above the market average75.91% above the market average
60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average
Price Chg 3m
68.41% above the market average68.41% above the market average68.41% above the market average68.41% above the market average68.41% above the market average
52.00% above the sector average52.00% above the sector average52.00% above the sector average52.00% above the sector average52.00% above the sector average

Technical Ratings

The Relative Strength Index measures a share price relative to itself and its recent history.

Momentum is an oscillator that measures the rate of price change.

RSI Not Available
Momentum 20 Not Available

Management Ratings

Operating Margin is profit as a percentage of sales.

Return on capital employed measures the return from invested and borrowed capital.

Operating Margin
99.68% below the market average99.68% below the market average99.68% below the market average99.68% below the market average99.68% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
ROCE Not Available

Profitability Ratings

Earnings per share, the company's profitability expressed on a per share basis.

Analysts' estimates of future EPS for the next 2 years.

EPS
42.82% below the market average42.82% below the market average42.82% below the market average42.82% below the market average42.82% below the market average
38.78% above the sector average38.78% above the sector average38.78% above the sector average38.78% above the sector average38.78% above the sector average
Forecast EPS Not Available

Profit/Loss Ratings

Monies produced from sales of goods and services after trade discounts, VAT, etc.

Operating Profit is the profit after deducting operating costs from gross profits.

Turnover
99.03% below the market average99.03% below the market average99.03% below the market average99.03% below the market average99.03% below the market average
94.44% below the sector average94.44% below the sector average94.44% below the sector average94.44% below the sector average94.44% below the sector average
Operating Profit Loss
47.16% below the market average47.16% below the market average47.16% below the market average47.16% below the market average47.16% below the market average
51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average

Balance Sheet Ratings

The difference between current assets and current liabilities.

A current asset representing the company's financial liquidity.

Assets
81.89% below the market average81.89% below the market average81.89% below the market average81.89% below the market average81.89% below the market average
78.72% below the sector average78.72% below the sector average78.72% below the sector average78.72% below the sector average78.72% below the sector average
Cash
58.94% below the market average58.94% below the market average58.94% below the market average58.94% below the market average58.94% below the market average
59.18% below the sector average59.18% below the sector average59.18% below the sector average59.18% below the sector average59.18% below the sector average

Director Deal Ratings

The cumulative amount of stocks sold by company directors over 1 year

The cumulative amount of stocks bought by company directors over 1 year

Sells 1y Not Available
Buys 1y Not Available

Broker Ratings

The percentage of stockbrokers that rate the company as a Buy

The percentage of stockbrokers that rate the company as a Hold

Brokers Percent Buy Not Available
Brokers Percent Neutral Not Available

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

N4 Pharma Market Data

Currency UK Pounds
Share Price 0.65p
Change Today 0.000p
% Change 0.00 %
52 Week High 3.07
52 Week Low 0.50
Volume 168,735
Shares Issued 394.78m
Market Cap £2.57m

N4 Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
43.35% below the market average43.35% below the market average43.35% below the market average43.35% below the market average43.35% below the market average
48% below the sector average48% below the sector average48% below the sector average48% below the sector average48% below the sector average
Value
43.35% below the market average43.35% below the market average43.35% below the market average43.35% below the market average43.35% below the market average
48% below the sector average48% below the sector average48% below the sector average48% below the sector average48% below the sector average
Income Not Available
Growth Not Available

N4 Pharma Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
13:32 214 @ 0.70p
13:17 9,273 @ 0.67p
12:14 255 @ 0.70p
11:23 50,000 @ 0.63p
11:22 3,726 @ 0.63p

N4 Pharma Key Personnel

CEO Nigel Theobald

Top of Page